Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir.

导出原文传递

翻译打印收藏纠错

作者： C,Bernardeschi ^[1] ; L,Valeyrie-Allanore ^[2] ; N,Ortonne ^[3] ; L,Gressier ^[4] ; N,Wallet-Faber ^[4] ; P-H,Bernard ^[5] ; C,Hezode ^[1] ; J-C,Duclos-Vallée ^[2] ; D,Samuel ^[1] ; V,Mallet ^[2] ; S,Pol ^[6] ; B,Milpied ^[4] ; N,Dupin ^[7]

作者单位： Department of Dermatology, Assistance-Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin, Paris, France. ^[1] Université Paris Descartes, Paris, France. ^[2] Department of Dermatology, Referral center for toxic bullous diseases, Assistance-Publique-Hopitaux de Paris, Hôpital Henri Mondor, Créteil, France. ^[3] Université Paris Est, Créteil, France. ^[4] Department of Pathology, Assistance-Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France. ^[5] Department of Hepatology, Hôpital Saint-André, Bordeaux, France. ^[6] Department of Hepatology, Assistance-Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Creteil, France. ^[7] Department of Hepatology, Assistance-Publique-Hôpitaux de Paris, Hôpital Paul Brousse, France. ^[8] Department of Hepatology, Assistance-Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin, Paris, France. ^[9] Department of Dermatology, Hôpital Saint-André Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. ^[10]